Beta 3 Adrenoreceptor Agonist for the Management of Lower Urinary Tract Symptoms in Men With Benign Prostatic Hyperplasia: A Systematic Review
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Beta-3 adrenoceptor (B3AR) agonist which mediate detrusor relaxation has been tried as a new treatment modality for men with benign prostatic hyperplasia (BPH). However, it remains unclear whether the B3AR agonist has more clinical benefits and fewer adverse effects in men with BPH than in women. We performed a comprehensive search using multiple databases, trials registries, other sources of grey literature, and conference proceedings regardless of language or publication status and included randomized controlled trials. Two review authors independently screened the literature, extracted data, and assessed risk of bias. We performed statistical analyses using a random-effects model and interpreted them according to the Cochrane Handbook for Systematic Reviews of Interventions. Primary outcomes were urologic symptom scores, quality of life (QoL), and overall adverse events. We found 4 randomized controlled trials with 1,105 participants in 3 comparisons. All studies reported short-term outcomes (ranged from 8 weeks to 12 weeks). Mirabegron, tamsulosin, silodosin, fesoterodine, and tadalafil were administrated as intervention. While B3AR agonist can improve the patient-important outcomes within group (before and after treatment), B3AR agonist combination therapy with current standard BPH treatment such as alpha blocker or anticholinergic may not have additional effects on urological symptom scores and QoL compared to alpha blocker or anticholinergic monotherapy. B3AR agonist therapy with phosphodiesterase 5 inhibitor (PDE5I) showed statistical improvement on urological symptom scores or QoL compared to PDE5I monotherapy. For safety profile, B3AR agonist in all 3 comparisons may not increase adverse event rate. While B3AR agonists may be used for the treatment of lower urinary tract symptoms in men with BPH if storage symptoms with standard BPH treatment are insufficient, B3AR agonists appear to have trivial or similar effects compared to current standard BPH treatment.
Abstract
Beta-3 adrenoceptor (B3AR) agonist which mediate detrusor relaxation has been tried as a new treatment modality for men with benign prostatic hyperplasia (BPH). However, it remains unclear whether the B3AR agonist has more clinical benefits and fewer adverse effects in men with BPH than in women. We performed a comprehensive search using multiple databases, trials registries, other sources of grey literature, and conference proceedings regardless of language or publication status and included randomized controlled trials. Two review authors independently screened the literature, extracted data, and assessed risk of bias. We performed statistical analyses using a random-effects model and interpreted them according to the Cochrane Handbook for Systematic Reviews of Interventions. Primary outcomes were urologic symptom scores, quality of life (QoL), and overall adverse events. We found 4 randomized controlled trials with 1,105 participants in 3 comparisons. All studies reported short-term outcomes (ranged from 8 weeks to 12 weeks). Mirabegron, tamsulosin, silodosin, fesoterodine, and tadalafil were administrated as intervention. While B3AR agonist can improve the patient-important outcomes within group (before and after treatment), B3AR agonist combination therapy with current standard BPH treatment such as alpha blocker or anticholinergic may not have additional effects on urological symptom scores and QoL compared to alpha blocker or anticholinergic monotherapy. B3AR agonist therapy with phosphodiesterase 5 inhibitor (PDE5I) showed statistical improvement on urological symptom scores or QoL compared to PDE5I monotherapy. For safety profile, B3AR agonist in all 3 comparisons may not increase adverse event rate. While B3AR agonists may be used for the treatment of lower urinary tract symptoms in men with BPH if storage symptoms with standard BPH treatment are insufficient, B3AR agonists appear to have trivial or similar effects compared to current standard BPH treatment.
참고문헌 (31)
- Irwin DE, "Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries:results of the EPIC study", Eur Urol, 50, pp.1306~1314 (2006)[DOI]
- Stewart WF, "Prevalence and burden of overactive bladder in the United States", World J Urol, 20, pp.327~336 (2003)
- Srikrishna S, "Management of overactive bladder syndrome", Postgrad Med J, 83, pp.481~486 (2007)
- Schena G, "Everything you always wanted to know about β(3)-AR *(* but were afraid to ask)", Cells, 8, pp.357~ (2019)
- Yamaguchi O, "Beta3-adrenoceptors in human detrusor muscle", Urology, 59, pp.25~29 (2002)
- Gormley EA, "Diagnosis and treatment of overactive bladder(non-neurogenic)in adults : AUA", SUFU guideline amendment, 2015, pp.193, 1572~1580
- Gratzke C, "EAU guidelines on the assessment of nonneurogenic male lower urinary tract symptoms including benign prostatic obstruction", Eur Urol, 67, pp.1099~1109 (2015)
- Yoshida M, "Vibegron, a novel potent and selective β(3)-adrenoreceptor agonist, for the treatment of patients with overactive bladder: a randomized, double-blind, placebo-controlled phase 3 study", Eur Ur, 73, pp.783~790 (2018)
- Athanasopoulos A, "An overview of the clinical use of antimuscarinics in the treatment of overactive bladder", Adv Urol, 2011, pp.820816~ (2011)
- Barry MJ, "Benign prostatic hyperplasia specific health status measures in clinical research : how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients", J Urol, 154, pp.1770~1774 (1995)
- Roehrborn CG, "Pathology of benign prostatic hyperplasia", Int J Impot Res (2008)
- Tubaro A, "Efficacy and safety of daily mirabegron 50 mg in male patients with overactive bladder : a critical analysis of five phase III studies", Ther Adv Urol, 9, pp.137~154 (2017)
- Lepor H, "The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia", N Engl J Med, 335, pp.533~539 (1996)
- Gravas S, "EAU guidelines on management of non-neurogenic male lower urinary tract symptoms (LUTS), incl. benign prostatic obstruction (BPO) 2020. European Association of Urology Guidelines", European Association of Urology Guidelines Office, ~ (2020)
- Mo W, "The β(3)-adrenoceptor agonist mirabegron increases human atrial force through β(1)-adrenoceptors : an indirect mechanism", Br J Pharmacol, 174, pp.2706~2715 (2017)
- Bragg R, "Mirabegron : a beta-3 agonist for overactive bladder", Consult Pharm, 29, pp.823~837 (2014)
- Higgins JP, "The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials", BMJ, 343, pp.d5928~ (2011)
- Egan KB, "The epidemiology of benign prostatic hyperplasia associated with lower urinary tract symptoms : prevalence and incident rates", Urol Clin North Am, 43, pp.289~297 (2016)
- Kakizaki H, "Mirabegron add-on therapy to tamsulosin for the treatment of overactive bladder in men with lower urinary tract symptoms: a randomized, placebo-controlled study (MATCH)", Eur Urol Focus, 6, pp.729~737 (2020)
- (2018)[URL]
- Matsukawa Y, "Factors contributing to the efficacy of two add-on therapies of fesoterodine or mirabegron to silodosin monotherapy for persistent overactive bladder in men with lower urinary tract symptoms", Int J Urol, 27, pp.85~86 (2020)
- Nitti V, "1869 Randomized, multicenter phase II study evaluating the urodynamic safety of mirabegron in males with lower urinary tract symptoms(LUTS)and bladder outlet obstruction(BOO)", J Urol, 187, pp.e756~ (2012)
- Nitti VW, "Results of a randomized phase III trial of mirabegron in patients with overactive bladder", J Urol, 189, pp.1388~1395 (2013)
- Ichihara K, "A randomized controlled study of the efficacy of tamsulosin monotherapy and its combination with mirabegron for overactive bladder induced by benign prostatic obstruction", J Urol, 193, pp.921~926 (2015)
- Kaplan SA, "Efficacy and safety of mirabegron versus placebo add-on therapy in men with overactive bladder symptoms receiving tamsulosin for underlying benign prostatic hyperplasia: a randomized, phase 4 study (PLUS)", J Urol, 203, pp.1163~1171 (2020)
- Matsukawa Y, "Comparison in the efficacy of fesoterodine or mirabegron addon therapy to silodosin for patients with benign prostatic hyperplasia complicated by overactive bladder: a randomized, prospective trial using urodynamic studies", Neurourol Urodyn, 38, pp.941~949 (2019)
- Yamanishi T, "A randomized controlled study of the efficacy of tadalafil monotherapy versus combination of tadalafil and mirabegron for the treatment of persistent overactive bladder symptoms in men presenting with lower urinary tract symptoms(CONTACT Study)", Neurourol Urodyn, 39, pp.804~812 (2020)
- Agarwal A, "What is the most bothersome lower urinary tract symptom? Individual-and population-level perspectives for both men and women", Eur Urol, 65, pp.1211~1217 (2014)
- Nitti VW, "Urodynamics and safety of the β3-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction", J Urol, 190, pp.1320~1327 (2013)
- Ogura K, "1091 Effects of add-on mirabegron on storage symptoms in men with lower urinary tract symptoms receiving alpha-1 blocker therapy", Eur Urol Suppl, 12, pp.e1091~ (2013)
- Kang TW, "Add-on treatment with mirabegron may improve quality of life in patients with benign prostatic hyperplasia complaining of persistent storage symptoms after tamsulosin monotherapy", Ther Adv Urol, 12, pp.1756287220974130~ (2020)